Top Markets
#1 Palladium Network Palladium Network +27.92%
#2 Siren Siren +24.71%
#3 Ankr Network Ankr Network +22.53%
#4 BankrCoin BankrCoin +21.15%
#5 Pons Pons +13.39%
#6 Status Status +12.03%
#7 Provenance Blockchain Provenance Blockchain +9.12%
#8 Hive Hive +9.05%
#9 Prom Prom +7.77%
#10 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.76%
Coin of the day
Palladium Network Palladium Network
Settings
Language
ENGLISH
Currency
USD
Theme
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc.

ARMP
Rank in Stocks #18285
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology... Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Share Price
$5.59
Last synced: 2026-09-02
Market Cap
$205.21M
Change (1 day)
6.27%
Change (1 year)
86.33%
Country
US
Trade Armata Pharmaceuticals, Inc. (ARMP)

Category

Healthcare
Revenue for Armata Pharmaceuticals, Inc. (ARMP)
Revenue in Sep 2026 TTM: 0
According to Armata Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Armata Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH